Workflow
澳华内镜:国内业绩承压,海外高速增长-20250505

Investment Rating - The investment rating for the company is "Accumulate" [4]. Core Views - The company reported a revenue of 750 million yuan in 2024, representing a year-on-year growth of 10.54%, but the net profit attributable to shareholders decreased by 63.68% to 21.01 million yuan [1]. - In Q1 2025, the company faced challenges with a revenue drop of 26.92% to 124 million yuan and a significant net loss of 28.79 million yuan, a decrease of 1143.36% year-on-year [1]. - Domestic revenue was under pressure due to reduced procurement activities, while overseas revenue grew significantly by 42.70% to 161 million yuan in 2024 [2]. Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 750 million yuan, with a year-on-year growth of 10.54%. However, the net profit attributable to shareholders was only 21.01 million yuan, down 63.68% from the previous year [1][8]. - The first quarter of 2025 saw a revenue decline to 124 million yuan, a 26.92% decrease year-on-year, and a net loss of 28.79 million yuan [1]. Domestic and Overseas Market - Domestic revenue for 2024 was 586 million yuan, growing by 3.93%, but limited by a decrease in procurement activities and tender amounts [2]. - The company expanded its overseas marketing network, resulting in a 42.70% increase in overseas revenue to 161 million yuan in 2024 [2]. Research and Development - The company invested 164 million yuan in R&D in 2024, an increase of 11.29%, accounting for 21.83% of total revenue [3]. - Significant product developments included the launch of various advanced endoscopic systems and tools aimed at improving diagnostic capabilities [3]. Profit Forecast - The revenue forecast for 2025-2027 is adjusted to 825 million yuan, 1.021 billion yuan, and 1.238 billion yuan respectively, with net profits expected to be 74 million yuan, 114 million yuan, and 164 million yuan [4][7]. - The earnings per share (EPS) are projected to be 0.55 yuan, 0.85 yuan, and 1.22 yuan for the years 2025, 2026, and 2027 respectively [7].